Table 1.
Baseline demographics
| Variable | HSD/hEDS (n = 72) | No HSD/hEDS (n = 72) | p-value |
|---|---|---|---|
| Basic Demographics | |||
| Age: Median (IQR) | 36 (27–48) | 36 (28–48) | 1.000 |
| BMI: Median (IQR) | 22.9 (19.6–27.8) | 24.6 (21.5–28.1) | 0.080 |
| Sex, n (% female) | 69 (96) | 69 (96) | 1.000 |
| Race, n (%) | < 0.001 | ||
| Caucasian | 62 (86) | 36 (50) | |
| Black | 0 (0) | 2 (3) | |
| Hispanic | 7 (10) | 10 (14) | |
| Asian | 2 (3) | 12 (16) | |
| Native American | 0 (0) | 6 (8) | |
| Obstetric History | |||
| History of Vaginal Delivery, n (%) | 14 (20) | 30 (43) | 0.003 |
| Co-morbidities | |||
| Diabetes, n (%) | 2 (3) | 6 (8) | 0.275 |
| IBS, n (%) | 41 (57) | 36 (50) | 0.504 |
| Functional Dyspepsia, n (%) | 22 (31) | 11 (15) | 0.046 |
| Anxiety, n (%) | 39 (54) | 23 (32) | 0.011 |
| Depression, n (%) | 37 (51) | 20 (28) | 0.006 |
| Chronic Pain Syndrome, n (%) | 27 (38) | 4 (6) | < 0.001 |
| Fibromyalgia, n (%) | 38 (53) | 13 (18) | < 0.001 |
| Migraine, n (%) | 38 (53) | 13 (18) | < 0.001 |
| Sleep Disorders, n (%) | 45 (63) | 18 (25) | < 0.001 |
| Narcotic Use, n (%) | 6 (8) | 1 (1) | 0.116 |
| Chronic Fatigue Syndrome, n (%) | 13 (18) | 8 (11) | 0.345 |
| Mast cell activation syndrome, n (%) | 7 (10) | 2 (3) | 0.166 |
| Endometriosis, n (%) | 10 (14) | 6 (8) | 0.427 |
| Gastrointestinal Symptoms | |||
| Abdominal Pain, n (%) | 59 (82) | 45 (62) | 0.015 |
| Nausea/Vomiting, n (%) | 45 (63) | 29 (40) | 0.012 |
| Dyspepsia, n (%) | 51 (71) | 26 (36) | < 0.001 |
| Constipation, n (%) | 70 (97) | 61 (85) | 0.017 |
| Diarrhea, n (%) | 28 (39) | 25 (35) | 0.730 |
Significant p<0.05 are in bold